Furthermore, Mellbin et al., in the DIGAMI 2 trial, linked systemic complement activation, potentially downstream of CD59 inactivation, to poor cardiovascular outcomes in type 2 diabetes patients’ post-myocardial infarction [10]. This evidence concerns the gene CD59 and type 2 diabetes mellitus.